Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 511,941
  • Shares Outstanding, K 74,087
  • Annual Sales, $ 0 K
  • Annual Income, $ -99,960 K
  • EBIT $ -109 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95

Options Overview Details

View History
  • Implied Volatility 211.66% (-6.94%)
  • Historical Volatility 72.61%
  • IV Percentile 35%
  • IV Rank 13.47%
  • IV High 1,059.77% on 03/24/26
  • IV Low 79.58% on 08/18/25
  • Expected Move (DTE 25) 0.54 (8.36%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 147
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 985
  • Open Int (30-Day) 1,400
  • Expected Range 5.97 to 7.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 5
  • High Estimate $-0.26
  • Low Estimate $-0.34
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) +70.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.01 +30.34%
on 03/30/26
7.01 -6.91%
on 04/17/26
+0.88 (+15.58%)
since 03/20/26
3-Month
5.01 +30.34%
on 03/30/26
8.00 -18.37%
on 03/09/26
-0.73 (-10.06%)
since 01/20/26
52-Week
2.43 +168.72%
on 05/15/25
10.99 -40.58%
on 12/23/25
+3.82 (+140.96%)
since 04/17/25

Most Recent Stories

More News
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness...

LXEO : 6.53 (-5.50%)
LXEO's Cardiac Gene Therapy Data Finally Arrives: The Pivot Wall Street Demanded or Another Clinical Stall?

Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...

LXEO : 6.53 (-5.50%)
LXEO's Cardiac Gene Therapy Data Finally Arrives: The Pivot Wall Street Demanded or Another Clinical Stall?

Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...

LXEO : 6.53 (-5.50%)
Payroll Figures Due in Canada Next Week

Monday Economic Lookahead Construction spending (delayed report) (Jan.) Featured Earnings ...

CNM : 50.00 (-1.56%)
HUMA : 0.6875 (-3.20%)
CNTA : 39.51 (-0.38%)
AIR : 121.97 (-0.87%)
IMMX : 10.09 (-2.51%)
SA : 33.04 (-1.67%)
CDZI : 4.97 (+2.69%)
SFD : 28.56 (-1.52%)
AGX : 611.21 (+2.23%)
LXEO : 6.53 (-5.50%)
PAYX : 93.09 (+1.23%)
SBC : 3.72 (-17.15%)
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

LX2020 generally well tolerated across ten participants with no clinically significant complement activation  LX2020 transduction, transcription, and increased protein expression observed across...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps ...

LXEO : 6.53 (-5.50%)
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 6.53 (-5.50%)

Business Summary

Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.

See More

Key Turning Points

3rd Resistance Point 7.28
2nd Resistance Point 7.12
1st Resistance Point 6.82
Last Price 6.53
1st Support Level 6.36
2nd Support Level 6.20
3rd Support Level 5.90

See More

52-Week High 10.99
Fibonacci 61.8% 7.72
Fibonacci 50% 6.71
Last Price 6.53
Fibonacci 38.2% 5.70
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.